BlossomHill Therapeutics (BLSM) Financials
BLSM
NASDAQ
Market Cap
$429.1M
as of Nov 6, 2026
Price / Sales
n/m
no revenue reported
Price / Earnings
n/m
no net income reported
Price / Book
n/m
negative shareholder equity, so no book multiple, Q2 FY2026
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 6, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Key Financial Metrics
No financial data available for BlossomHill Therapeutics, Inc..
Financial data is sourced from SEC filings. This company may not have filed yet or may trade on a non-US exchange.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Altimmune, Inc. ALT | FY2025 | $41K | -$88.1M | N/A | $404.6M | — |
| Allogene Therapeutics, Inc. ALLO | FY2025 | $0 | -$190.9M | N/A | $359.3M | — |
| Assembly Biosciences, Inc ASMB | FY2025 | $72.3M | -$6.1M | -8.5% | $415.8M | 88/100 |
| Editas Medicine, Inc. EDIT | FY2025 | $40.5M | -$160.1M | N/A | $394.7M | 45/100 |
| Rezolute, Inc. RZLT | FY2026 | N/A | -$77.6M | N/A | $375.3M | — |